Evidence map›Paper›PMID 39434179›Full record

ArticleTrials2024

Telehealth-delivered cognitive rehabilitation for people with cognitive impairment as part of the post-COVID syndrome: protocol for a randomised controlled trial as part of the CICERO (Cognitive Impairment in Long COVID: Phenotyping and Rehabilitation) study.

Martina Vanova, Aysha Mohamed Rafik Patel, Iona Scott, Gina Gilpin, Emily N Manning, Charlotte Ash, Philippa Wittenberg, Jason Lim, Zoe Hoare, Rachel Evans and 9 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05731570 (Cognitive Impairment in Long Covid), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05731570 naunknown statusnot on this map

Cognitive Impairment in Long Covid: PhEnotyping and RehabilitatiOn (CICERO)

TypeinterventionalSponsorUniversity College, LondonRan2023 to 2024Enrolled78ConditionsLong Covid19ArmsCognitive rehabilitation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Martina VanovaDementia Research Centre, Faculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London, London, UK. m.vanova@ucl.ac.uk.ORCID http://orcid.org/0000-0002-1329-7566
Aysha Mohamed Rafik PatelInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0009-0004-4987-8217
Iona ScottInstitute of Cognitive Neuroscience, University College London, London, UK.
Gina GilpinInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0000-0002-9441-7979
Emily N ManningInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0000-0002-4505-3611
Charlotte AshInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0009-0007-2591-9637
Philippa WittenbergInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0009-0003-8583-7896
Jason LimSchool of Applied Sciences, University of Brighton, Brighton, UK.ORCID http://orcid.org/0000-0001-6397-3131
Zoe HoareNorth Wales Medical School, Bangor University, Bangor, UK.ORCID http://orcid.org/0000-0003-1803-5482
Rachel EvansNorth Wales Medical School, Bangor University, Bangor, UK.ORCID http://orcid.org/0000-0003-0960-9843
Nathan BraySchool of Health Sciences, Bangor University, Bangor, UK.ORCID http://orcid.org/0000-0001-7646-5435
Christopher M KippsDepartment of Neurology, University Hospitals Southampton NHS Trust, Southampton, UK.ORCID http://orcid.org/0000-0002-5205-9712
Ciara DevineDepartment of Neurology, University Hospitals Southampton NHS Trust, Southampton, UK.ORCID http://orcid.org/0009-0008-9107-1045
Saliha AhmedGM Dementia Research Centre, Greater Manchester Mental Health NHS Trust, Manchester, UK.
Ross DunneGM Dementia Research Centre, Greater Manchester Mental Health NHS Trust, Manchester, UK.
Anna KoniotesDepartment of Neurology, University Hospitals Sussex NHS Trust, Brighton, UK.ORCID http://orcid.org/0009-0000-7009-6456
Catherine WarrenDepartment of Neurology, University Hospitals Sussex NHS Trust, Brighton, UK.ORCID http://orcid.org/0009-0002-0119-820X
Dennis Chan *Institute of Cognitive Neuroscience, University College London, London, UK.ORCID http://orcid.org/0000-0002-4265-3718
Aida Suarez-Gonzalez *Dementia Research Centre, Faculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0000-0002-0904-1031

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBetween 25 and 75% of people with persistent post-acute sequelae of SARS-CoV-2 infection (PASC) experience cognitive difficulties, compromising functional ability, quality of life, and activities of daily living, including work. Despite this significant morbidity, there is a paucity of interventions for this disorder that have undergone evaluation within a formal trial setting. Therefore, we have developed a cognitive rehabilitation programme, specifically designed to address the cognitive symptoms of PASC, notably impaired attention and processing speed, while also accounting for other PASC symptoms (fatigue, post-exertional malaise) that may aggravate the cognitive impairment. This study protocol outlines a randomised controlled trial (RCT) designed to evaluate the effectiveness of this programme compared to standard clinical care.

methodsThis is a multi-centre, parallel-group, individually randomised controlled trial, comparing standard clinical care with and without cognitive rehabilitation. We will recruit 120 non-hospitalised adults (aged 30-60 years) from three NHS sites in England with a history of COVID-19 infection and cognitive impairment persisting more than 3 months after the acute infection. Participants will be randomised (1:1) to the intervention or control groups, with the latter represented as a provision of standard clinical care without cognitive rehabilitation. The cognitive rehabilitation programme consists of ten 1-hour sessions, delivered weekly. Outcomes will be collected at baseline, 3, and 6 months, with participant-defined goal-attainment scores, relating to functional goals, at 3 months as the primary outcome measure. Secondary outcomes will be cognitive function, measures of quality of life, social functioning, mental health, fatigue, sleep, post-exertional malaise, and social and health care service use. We will also evaluate the health-economic benefits of cognitive rehabilitation in this population. DISCUSSION: Cognitive impairment in PASC is a major cause of functional disability with no effective treatment. Accordingly, we will undertake an RCT of cognitive rehabilitation, the protocol of which is published here. If this trial is successful in delivering improvements in trial outcomes, it will address a major unmet need relating to this emergent disorder, with a significant impact on affected individuals and the wider health economy.

trial registrationClinicalTrials.gov NCT05731570. Registered on February 16, 2023.

Indexed as

Cognitive DysfunctionCOVID-19Post-Acute COVID-19 SyndromeRandomized Controlled Trials as TopicAdultCognitionCognitive Behavioral TherapyCognitive TrainingEnglandFemaleHumansMaleMiddle AgedMulticenter Studies as TopicQuality of LifeSARS-CoV-2Cognitive rehabilitationCOVID-19Post-acute sequele of SARS-COV-2

Identifiers

PMID39434179
PMCPMC11494741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.